摘要
目的评价长春瑞滨(NP)或吉西他滨(GP)联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效和成本效用。方法 60例晚期NSCLC患者,每组30例,化疗4周期后,评价疗效和成本效用。结果 NP组和GP组治疗的有效率分别为36.6%和40.0%,中位生存期分别为8.52和8.37月,统计学检验发现两者之间的差异无统计学意义,P>0.05。NP组和GP组治疗的一年生存率分别为36.6%和33.3%;2年生存率分别为16.6%和13.3%,成本效用比分别为1 123.41和1 556.61。结论 NP和GP方案治疗NSCLC疗效基本相似,但NP方案治疗的成本效用相对较好。
Objective To compare and evaluate the effectiveness and cost utility of vinorelbine versus gemcitabine combined with cisplatin of advanced non-small cell lung cancer. Methods 60 advanced patients wit NSCLC were enrolled into two groups , the effectiveness and cost utility were evaluated after 2 cycles. Results The efficacy rate wit NP and GP were 36.6 % and 40.0 % respectively, An existence period wit NP and GP were 8.52 and 8.37 respectively, showing no significant difference （P 〉 0. 05） between the two groups. One year survival rate with NP and GP were 36.6 % and 40.0 % respectively; two year survival rate with NP and GP were 16.6 % and 13.3% respectively. The ratio of cost utility with NP and GP were 1123.41and 1556.61 respectively. Conclusion The effectiveness of NP versus GP of advanced non-small cell lung cancer was similar, the cost utility of NP was more than GP.
出处
《药学实践杂志》
CAS
2012年第6期462-463,480,共3页
Journal of Pharmaceutical Practice
基金
浦东新区卫生系统医学领先人才培养项目(PWRd2007-12)资助
关键词
长春瑞滨
吉西他滨
顺铂
晚期非小细胞肺癌
化疗
成本效用分析
vinorelbine
gemcitabine
eisplatin
advanced non-small cell lung cancer
chemotherapy
cost utility analysis
